chemotherapy for breast cancer

From Aaushi
Jump to navigation Jump to search

Introduction

Also see breast cancer (management)

Indications

* consider life expectancy, functional status, & comorbidities prior to administering chemotherapy[17]

Contraindications

Complications

Management

* anthracycline-based chemotherapy for triple-negative breast cancer[17]

Notes

More general terms

Additional terms

References

  1. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 669
  2. Formulary Update, Kaiser Permanente Northern California, summer, 2000
  3. 3.0 3.1 Prescriber's Letter 8(5):29 2001
  4. 4.0 4.1 Journal Watch 24(15):120, 2004 Zander AR, Kroger N, Schmoor C, Kruger W, Mobus V, Frickhofen N, Metzner B, Schultze W, Berdel WE, Koenigsmann M, Thiel E, Wandt H, Possinger K, Trumper L, Kreienberg R, Carstensen M, Schmidt EH, Janicke F, Schumacher M, Jonat W. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol. 2004 Jun 15;22(12):2273-83. Epub 2004 Apr 26. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15111618
    Hortobagyi GN. What is the role of high-dose chemotherapy in the era of targeted therapies? J Clin Oncol. 2004 Jun 15;22(12):2263-6. Epub 2004 Apr 26. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15111620
  5. 5.0 5.1 Journal Watch 25(8):67, 2005 Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ. 2005 Jan 29;330(7485):217. Epub 2005 Jan 13. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/15649903 <Internet> http://bmj.bmjjournals.com/cgi/content/full/330/7485/217
  6. 6.0 6.1 Guarneri V et al, Long-term cardiac tolerability of trastuzumab in metastatic breast cancer. The M.D. Andersion Cancer Center experience. J Clin Oncol 2006, 24:4107 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16908934
    Harris EE et al, Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol 2006, 24:4100 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16908933
  7. Evidence-based Series #1-17: Section 1 The role of HER2/neu in systemic and radiation therapy for women with breast cancer: A clinical practice guideline http://www.cancercare.on.ca/pdf/pebc1-17s.pdf
  8. 8.0 8.1 Jones SE et al, Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006, 24:5381 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17135639
  9. 9.0 9.1 Smith I et al, 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial. Lancet 2007, 369:29 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17208639
  10. 10.0 10.1 10.2 Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine- responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17200148
  11. Coombes RC et al, Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 2007, 369:559 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17307102
  12. 12.0 12.1 Muss HB et al Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009 May 14; 360:2055. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19439741
  13. 13.0 13.1 Koppelmans V et al. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 2012 Feb 27 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22370315 <Internet> http://jco.ascopubs.org/content/early/2012/02/27/JCO.2011.37.0189
  14. 14.0 14.1 14.2 Loibl S et al Treatment of breast cancer during pregnancy: an observational study The Lancet Oncology, Early Online Publication, 16 August 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22902483 <Internet> http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70261-9/abstract
  15. 15.0 15.1 The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature (2012) Sept 23, <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23000897 <Internet> http://www.nature.com/nature/journal/vaop/ncurrent/full/nature11412.html
  16. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010 Nov 11;363(20):1938-48. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21067385
  17. 17.0 17.1 17.2 17.3 17.4 17.5 Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 2018.
  18. 18.0 18.1 Janelsins MC, Heckler CE, Peppone LJ et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: An analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol 2016 Dec 28; PMID: https://www.ncbi.nlm.nih.gov/pubmed/28029304
  19. 19.0 19.1 Bankhead C Six Months of Trastuzumab Equal to 12 in Breast Ca - Similar outcomes and less cardiotoxicity, but more research needed. MedPage Today. May 16, 2018 https://www.medpagetoday.com/meetingcoverage/asco/72917
    Earl HM, et al PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. American Society of Clinical Oncology (ASCO) 2018; Abstract 506
  20. 20.0 20.1 FDA Approval Notice. March 8, 2019 FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633065.htm
  21. 21.0 21.1 MedPage Today Staff. Feb 3, 2020 HER2 Breast Cancer Treatment Effective on Brain Metastases - Patients with brain metastases have historically been excluded from most clinical trials. https://www.medpagetoday.com/meetingcoverage/sabcsvideopearls/84671
  22. 22.0 22.1 Ma SJ, Oladeru OT, Singh AK et al. Association of survival with chemoendocrine therapy in women with small, hormone receptor-positive, ERBB2-positive, node-negative breast cancer. JAMA Netw Open 2020 Apr 1; 3:e202507 PMID: https://www.ncbi.nlm.nih.gov/pubmed/32271387 Free PMC Article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2764231
  23. 23.0 23.1 Bankhead C Donepezil Flunks Test for Chemotherapy-Related Cognitive Impairment. No improvement versus placebo in immediate recall or other outcomes in breast cancer survivors. MedPage Today May 14, 2024 https://www.medpagetoday.com/hematologyoncology/breastcancer/110123
    Rapp SR et al Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116). J Clin Oncol. 2024. May 6 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38709986 https://ascopubs.org/doi/10.1200/JCO.23.01100